| Previous Close | 0.99 |
| Open | 1 |
| Day High | 1.15 |
| Day Low | 0.99 |
| 52-Week High | 1.19 |
| 52-Week Low | 0.56 |
| Volume | 566,230 |
| Average Volume | 188,525 |
| Market Cap | 13.83M |
| PE | -1.1 |
| EPS | -0.98 |
| Moving Average 50 Days | 0.99 |
| Moving Average 200 Days | 0.91 |
| Change | 0.09 |
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
GlobeNewswire Inc.
Mar 09, 2026 9:25 PM GMT
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will r
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
GlobeNewswire Inc.
Mar 09, 2026 1:15 PM GMT
• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further clinical development • Acne vulgaris represents a promisin
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
GlobeNewswire Inc.
Feb 26, 2026 2:15 PM GMT
WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S.